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Introduction
In patients with recent onset schizophrenia, cannabis use dis­
orders (CUDs) are highly comorbid and associated with an 
unfavourable outcome.1–3 In several studies, patients who 
used cannabis were found to have an earlier age at onset of 
their first psychotic episode,4–7 suggesting that cannabis may 
trigger the onset of schizophrenia.
Patients with schizophrenia have morphological differ­
ences compared with healthy individuals, including several 
smaller brain regions8 and decreased cerebral lateraliza­
tion.9 However, an important question is whether these vol­
ume reductions are modulated by a comorbid CUD. Two 
systematic reviews10,11 evaluated studies on differences in 
brain morphology between patients with and without 
CUDs. However, no definite conclusions could be drawn 
owing to differences between studies in duration of canna­
bis use, presence of other comorbid (substance use) disor­
ders, medication use, sex and differences in disease charac­
teristics, which have all been found to be related to grey 
matter volume decreases in schizophrenia.10 The use of a 
more homogeneous sample (i.e., including only patients 
with recent onset schizophrenia) would diminish these con­
founding effects, but so far few studies in patients with re­
cent onset schizophrenia have been published. Some studies 
show smaller volumes in the CUD group,12–15 whereas oth­
ers found no volumetric differences between patients with 
and without (NCUD) CUDs16–20 or an increase in grey matter 
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Background: Schizophrenia is highly comorbid with cannabis use disorders (CUDs), and this comorbidity is associated with an unfavour-
able course. Early onset or frequent cannabis use may influence brain structure. A key question is whether comorbid CUDs modulate brain 
morphology alterations associated with schizophrenia. Methods: We used surface-based analysis to measure the brain volume, cortical 
thickness and cortical surface area of a priori–defined brain regions (hippocampus, amygdala, thalamus, caudate, putamen, orbitofrontal 
cortex, anterior cingulate cortex, insula, parahippocampus and fusiform gyrus) in male patients with schizophrenia or related disorders with 
and without comorbid CUDs and matched healthy controls. Associations between age at onset and frequency of cannabis use with regional 
grey matter volume were explored. Results: We included 113 patients with (CUD, n = 80) and without (NCUD, n = 33) CUDs and 84 con-
trols in our study. As expected, patients with schizophrenia (with or without a CUD) had smaller volumes of most brain regions (amygdala, 
putamen, insula, parahippocampus and fusiform gyrus) than healthy controls, and differences in cortical volume were mainly driven by corti-
cal thinning. Compared with the NCUD group, the CUD group had a larger volume of the putamen, possibly driven by polysubstance use. 
No associations between age at onset and frequency of use with regional grey matter volumes were found. Limitations: We were unable to 
correct for possible confounding effects of smoking or antipsychotic medication. Conclusion: Patients with psychotic disorders and comor-
bid CUDs have larger putamen volumes than those without CUDs. Future studies should elaborate whether a large putamen represents a 
risk factor for the development of CUDs or whether (poly)substance use causes changes in putamen volume.
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density.21 Importantly, all studies included in these reviews 
had small samples (6–30) of patients with CUDs.
Because an earlier age at onset of cannabis use and a higher 
frequency of cannabis use may increase the risk for schizo­
phrenia, 22–25 it is possible that these factors influence brain 
morphology. In nonschizophrenic participants with a CUD, 
grey matter volume was positively correlated with age at onset 
but not with duration of cannabis use, 26 suggesting that the as­
sociation between cannabis use and brain volume resulted 
from abnormal brain development rather than neurodegenera­
tion caused by cannabis. However, Cousijn and colleagues27 
found that volume reductions between cannabis users and 
controls did not differ significantly, but still correlated with the 
amount of cannabis used and the severity of cannabis depend­
ence. This finding was corroborated by  Battistella and col­
leagues,28 who reported an effect of dosage as well, since regu­
lar cannabis users had decreased grey matter volumes in the 
temporal pole and parahippocampal gyrus compared with oc­
casional users. Lorenzetti and colleagues29,30 described in their 
reviews a trend for decreases in brain volumes in samples with 
high­ but not low­frequency cannabis use, all of which sug­
gests an adverse effect of cannabis.
Most studies on brain abnormalities in (recent onset) schizo­
phrenia used volumetric techniques to assess grey matter dif­
ferences between patients and controls. However, these tech­
niques cannot differentiate between cortical thickness and 
cortical surface area. As cortical volume is a product of both 
measures, cortical volume changes can result from changes in 
cortical thickness, surface area or both. This distinction is im­
portant because changes in cortical thickness and cortical sur­
face area occur at different stages of development.31–33 While 
cortical surface area seems to develop according to a fixed 
maturation course,34 cortical thickness is also influenced by ex­
ternal factors, such as substance use.32,35 In addition, there is a 
reduced cortical cerebral asymmetry in patients with schizo­
phrenia,9 which can also be influenced by substance use, as 
there is decreased cortical thickness and altered thickness 
asymmetry in individuals with cocaine dependence.35
The aim of the present study was 2­fold. First, we sought 
to identify differences in brain volume, cortical thickness, 
cortical surface area and cortical symmetry in a large and 
relatively homogeneous group of male patients with recent 
onset schizophrenia with and without comorbid CUDs and 
a group of matched healthy controls. Second, we investi­
gated the association between brain volume and age of on­
set and frequency of cannabis use in patients with schizo­
phrenia. We hypothesized that both patient groups would 
show decreased regional brain volumes compared with 
healthy controls in regions previously found to be related to 
schizophrenia.8,36 Also, we hypothesized that patients in the 
CUD group would show decreased brain volumes com­
pared with those in the NCUD group in regions previously 
found to be related to cannabis use and CUDs.10,12,19,37 Re­
gions of interest (ROIs) were the hippocampus, amygdala, 
anterior cingulate gyrus, orbitofrontal gyrus, fusiform 
 gyrus, insula, parahippocampus, thalamus, caudate and 
 putamen. Furthermore, we hypothesized that these differ­
ences in regional brain volumes would be driven by differ­
ences in cortical thinning rather than by differences in corti­
cal surface area38 and that patients would show decreased 
cerebral lateralization, reflected by decreased cortical sym­
metry, compared with controls and that this lateralization 
would be even more pronounced in patients with a CUD.9 
Finally, we hypothesized that an earlier age of onset and a 
higher frequency of regular cannabis use would both be re­
lated to larger decreases in these ROIs.
Methods 
 
Participants and clinical assessments
Data were extracted from the charts of patients admitted to 
the Early Psychosis Department of the Academic Medical 
Center, Amsterdam, the Netherlands, between June 2004 and 
December 2011. The ethics committee of the Academic Medi­
cal Center gave permission to use the fully anonymized, rou­
tinely collected patient data. Before MRI assessment, we ob­
tained verbal informed consent from patients; whenever 
participants with psychosis were deemed not capable of giv­
ing informed consent, we obtained consent from their care­
takers. From the patient charts, we obtained information 
from diagnostic interviews based on the Comprehensive As­
sessment of Symptoms and History39 conducted by experi­
enced clinicians. The DSM­IV diagnoses of schizophrenia, 
schizophreniform, schizoaffective and other psychotic disor­
ders, which we hereafter refer to as schizophrenia for reasons 
of brevity) were based on this interview and on additional 
 interviews with parents and available patient history. In ad­
dition, we collected information on cannabis use and other 
substance use disorders. Nicotine use was dichotomously as­
sessed as current use or no current use. Because our sample 
included only 2 female patients with CUDs, we decided to 
include only male patients. This diminished heterogeneity, as 
sex has been found to influence brain morphology in patients 
with schizophrenia40 and in healthy cannabis users.41 Patients 
were included in the CUD group if they had a DSM­IV diag­
nosis of cannabis abuse or dependence; they were included 
in the NCUD group if they had a maximum lifetime use of 
cannabis of 5 times.
We selected age­matched healthy controls from a series of 
different studies performed at the Academic Medical Center 
between June 2004 and December 2011 for which the ethics 
committee provided approval. Written informed consent 
was obtained from all controls. Controls were excluded if 
they met criteria for any lifetime DSM­IV Axis­1 disorder, 
including CUDs, or if they used any psychotropic drug at 
the time of scanning.
MRI acquisition and processing
All structural MRI scans were acquired on the same 3 T MRI 
scanner (Intera, Philips Healthcare) with a phased array 
SENSE 6/8­channel receiver head coil. For each participant, a 
T1­weighted structural MRI image was acquired. We 
performed cortical reconstruction and volumetric segmenta­
tion using the FreeSurfer image analysis suite version 5.0.0 
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(http://surfer.nmr.mgh.harvard.edu/) on the e­Bioinfra 
Gateway,42 a Web application that provides facilitated access 
to the Dutch Grid infrastructure to analyze large data sets. In 
some scans, manual editing of pial surfaces was necessary; this 
was carefully conducted according to established guidelines.
Statistical analysis
Demographic characteristics were compared between patient 
groups and healthy controls using the χ2 or Mann–Whitney 
U tests for discrete variables and 2­sample t tests for nor­
mally distributed continuous variables. The FreeSurfer pro­
cessing steps generate different output variables for each par­
ticipant, which we extracted from the FreeSurfer output files 
using Matlab version 7.8.0.347 (R2009a) and transferred into 
SPSS version 18 (SPSS Inc.). We selected the ROIs before 
analy sis according to the literature.10,19,37 We calculated the 
mean volume and surface measures as well as the mean 
thickness measures (weighted for cortical surface area) of the 
left and right hemispheres.
For each brain region, the effect of group (CUD, NCUD, 
control) was assessed using a linear regression model with 
brain volume as the dependent variable and group, age, slice 
thickness and appropriate global measure as independent 
variables. The global measure included in the model for vol­
ume was intracranial volume, for surface area it was the sum 
of the total left and right surface area, and for cortical thickness 
it was the mean cortical thickness, weighted by surface area. 
Slice thickness and pixel spacing both differed between 
groups; however, they were strongly correlated, so only slice 
thickness was included as an additional predictor in the 
model. All possible interaction terms were first added to the 
model and subsequently removed in a backward elimination 
procedure when they were not significant. We performed sim­
ilar statistical analyses to assess differences in cortical thickness 
and cortical surface area for each region. To control for the 
number of statistical tests we used a Bonferroni correction 
based on the number of ROIs, adjusted for the correlation be­
tween the ROIs.43,44 For the volumes (11 ROIs with an average r 
of 0.359 between the regions) this resulted in a critical α of 0.01. 
For the cortical thickness (5 ROIs with an average r of 0.45) and 
surface area (5 ROIs with an average r of 0.57) calculations the 
critical α were 0.02 and 0.03, respectively.
We report the overall effect of group status on regional brain 
volume and, if significant, the separate estimate and standard 
error values per pairwise comparison. To compare the magni­
tudes of the significant effects, we calculated  Cohen d scores. 
These analyses were repeated after exclusion of patients who 
used illicit substances other than cannabis. In addition, we re­
peated the analyses with nicotine use (yes v. no) as an addi­
tional covariate. Owing to missing data, these analyses were 
performed in a smaller sample (n = 76 in the CUD  group, 5% 
missing values; n = 33 in the NCUD group; no missing values; 
n = 49 in the control group, 42% missing values).
Within the CUD group, a similar statistical procedure 
was used to assess the association between grey matter vol­
umes and the frequency and age of onset of cannabis use. 
For frequency of use, patients were divided in 2 groups: 
high  frequency (daily) and low frequency (weekly or less 
than weekly use of cannabis).
To assess cortical symmetry, we separated the raw cortical 
thickness data of the left and right hemispheres from the total 
cortical thickness and 5 cortical ROIs (orbitofrontal cortex [OFC], 
anterior cingulate cortex (ACC), insula, parahippocampus and 
fusiform gyrus). We performed a paired t test for all of these re­
gions for each group (CUD, NCUD, control) separately.45
Results 
 
Demographic and clinical variables
We included 113 patients with schizophrenia (80 in the CUD 
group and 33 in the NCUD group) and 84 healthy controls in 
our study. There were no significant differences in age 
among the groups (CUD: 22.18 ± 2.74 yr; NCUD: 22.15 ± 3.04 
yr; control: 23.19 ± 3.48 yr, c22 = 3.96, p = 0.14). Also, no differ­
ences were found between the CUD and NCUD groups for 
any demographic or clinical characteristics (Table 1). Re­
markably, the age at onset of first psychosis was very similar 
in the CUD and NCUD groups. With regard to nicotine use, 
patients in the CUD group were more likely to smoke ciga­
rettes (71 smokers v. 5 nonsmokers) than those in the NCUD 
group (7 smokers v. 26 nonsmokers) and healthy controls 
(10 smokers v. 39 nonsmokers, c22 = 84.46, p < 0.001).
Regarding the frequency of cannabis use, 57 patients in the 
CUD group were daily users (71.3%), 17 (21.3%) were weekly 
users and 5 (6.3%) used less than weekly. The mean age at 
onset of regular cannabis use was 15.81 ± 3.10 years.
MRI data
Results of the scanning secquences are summarized in 
 Table 2. We found no significant differences in total cortical 
grey matter volume among the groups (Table 3). Also, there 
were no associations between total grey matter volume and 
age at onset or frequency of cannabis use in the CUD group 
(Appendix, Tables S1 and S2, available at jpn.ca). 
Figure 1 summarizes the results of the volume analyses. It 
depicts the percentage deviation of the mean volume of the 
control group per ROI. For the subcortical volumes, we 
found an effect of group on the volume of the amygdala and 
putamen (Table 3). The pairwise comparisons (Table 4) 
showed that both patient groups had smaller amygdala vol­
umes (CUD v. control: d = 1.24; NCUD v. control: d = 1.73) 
and putamen volumes (CUD v.control: d = 0.70; NCUD v. 
control: d = 1.33) than healthy controls. Patients with CUDs 
showed significantly larger putamen volumes than NCUD 
patients (d = 0.51). All analyses were run a second time using 
voxel­based morphometry in SPM8 (default settings, includ­
ing modulation). Results were similar except that the CUD 
group showed higher grey matter density in the left (t = 3.79, 
cluster size = 224,  pFWEcor = 0.016) and right thalamus (t = 3.81, 
cluster size = 225, pFWEcor = 0.016). Effect sizes were comparable 
after exclusion of multiple substance users (n = 50 in the 
CUD and n = 33 in the NCUD groups) and in the analyses in­
cluding nicotine use as a covariate. However, in both these 
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analyses the difference between the CUD and NCUD groups 
in the putamen no longer reached significance (Appendix, 
Table S3 and S4).
In the CUD group, we observed a positive trend for the 
correlation between the frequency of cannabis use and the 
volume of the caudate (F = 5.70, p = 0.019; Appendix, 
Table  S2), which did not survive the multiple comparison 
correction. We found no significant correlation between 
regional volume and age at onset of regular cannabis use 
(Appendix, Table S1).
Table 1: Demographic and clinical characteristics in patients with schizophrenia with and without comorbid 
cannabis use disorders
Group, no.(%)*
Characteristic CUD, n = 80 NCUD, n = 33 Statistic p value
Age, mean ± SD, yr 22.18 ± 2.7 22.15 ± 3.0 t111 = 0.040 0.97
Age onset first psychosis, mean ± SD, yr 20.40 ± 3.3 20.24 ± 3.4 t111 = 0.228 0.82
Duration of positive symptoms, median, mo 11 14 U = 1156 0.30
Duration of psychotic disorder, median, yr 1 1 U = 1258 0.69
GAF score, mean ± SD 34.29 ± 10.6 34.55 ± 11.0 t111 = –0.117 0.91
Nicotine use 71 (89.0) 7 (21.2) c21 = 58.95 < 0.001
Education χ24 = 2.207 0.82
Primary education 1 (1.3) —
Lower secondary professional education 17 (21.3) 5 (15.2)
Higher secondary education 42 (52.5) 15 (45.5)
Higher professional education 11 (13.8) 7 (21.2)
University 9 (11.3) 5 (15.2)
Missing — 1 (3.0)
Specific psychotic disorders c24 = 2.411 0.66
Schizophrenia 57 (71.3) 24 (72.7)
Schizophreniform disorder 7 (8.8) 5 (15.2)
Schizoaffective disorder 13 (16.3) 4 (12.1)
Substance induced psychotic disorder 2 (2.5) —
Psychotic disorder NOS 1 (1.3) —
Number of psychotic episodes c22 = 1.08 0.58
1 67 (83.8) 29 (87.9)
2 12 (15.0) 3 (9.1)
3 1 (1.3) 1 (3.0)
Medication use c22 = 0.247 0.88
Atypical antipsychotics 65 (81.3) 28 (84.9)
Typical antipsychotics 7 (8.8) 3 (9.1)
None 7 (8.8) 2 (6.1)
Duration of medication use, median, mo 4 5 U = 903 0.47
Comorbid DSM-IV diagnoses c26 = 5.026 0.54
Affective disorder 2 (2.5) 1 (3.0)
Anxiety disorder — 1 (3.0)
Obsessive–compulsive disorder 1 (1.3) 2 (6.1)
Posttraumatic stress disorder 1 (1.3) 1 (3.0)
Pervasive developmental disorder 1 (1.3) 1 (3.0)
ADHD 3 (3.8) —
Other 3 (3.8) 1 (3.0)
Comorbid DSM-IV drug diagnoses c25 = 5.577 0.35
Alcohol abuse 10 (12.5) 4 (12.1)
Alcohol dependency 5 (6.3) —
Cocain abuse 2 (2.5) —
Cocain dependency 1 (1.3) —
Amphetamine abuse — —
Amphetamine dependency 2 (2.5) —
Multiple 7 (8.8) —
ADHD = attention-deficit/hyperactivity disorder; CUD = cannabis use disorder; GAF = Global Assessment of Functioning; NCUD = no cannabis 
use disorder; NOS = not otherwise specified; SD = standard deviation. 
*Unless otherwise indicated.
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For the cortical volumes, we found an effect of group on 
brain volume in the insula, parahippocampus and fusiform 
gyrus (Fig. 1, Table 3). Pairwise comparisons showed signifi­
cant differences between patients and healthy controls in the 
insula (CUD v. control: d = 0.57), parahippocampus (CUD v. 
control: d = 0.76; NCUD v. control: d = 1.23) and fusiform 
 gyrus (CUD v. control: d = 0.80; NCUD v. control: d = 0.87), 
with smaller volumes in the patient groups (Table 4). Effect 
sizes of these differences were comparable after exclusion of 
multiple substance users and in the analyses including nico­
tine use as a covariate (Appendix, Table S3 and S4). There 
were no significant correlations with age at onset or 
Table 2: Scanning sequences of all participants (n = 197), by group
Group, no. (%)*
Parameter CUD, n = 80 NCUD, n = 33 Control, n = 84 Statistic p value
Pixel spacing, mean ± SD, mm† 0.84 ± 0.2 0.79 ± 0.2 0.96 ± 0.1 Welch t2,65 = 28.51 < 0.001
TR, mean ± SD (range), ms 9.6 ± 0.3 (9.0–9.8) 9.6 ± 0.3 (9.0–9.8) 9.6 ± 0.2 (9.0–9.7) Welch t2,73 = 0.001 0.99
TE, mean ± SD (range), ms 4.4 ± 0.4 (3.5–4.6) 4.4 ± 0.4 (3.7–4.6) 4.5 ± 0.3 (3.5–4.6) Welch t2,81 = 3.13 0.049
Slice thickness, mm c22 = 7.99 0.018
1.0 16 (20.0) 8 (24.2) 6 (7.1)
1.2 64 (80.0) 24 (72.7) 78 (92.9)
Flip angle of 8° 80 (100) 33 (100) 84 (100)
CUD = cannabis use disorder; NCUD = no cannabis use disorder; SD = standard deviation; TE = echo time; TR = repetition time. 
*Unless otherwise indicated. 
†Pixel spacing is the same in both dimensions (i.e., x and y).
Table 3: Mixed model analyses of the effect of group on brain volume, cortical thickness and surface area*
Group, mean ± SD†
Brain region CUD, n = 80 NCUD, n = 33 Control, n = 84 F p value‡
Total grey matter volume§ 480399 ± 48604 507985 ± 47218 496952 ± 44090 4.12 0.018
Hippocampus volume§ 4272 ± 465 4340 ± 469 4337 ± 417 0.09 0.92
Amygdala volume§ 1754 ± 238 1670 ± 190 2042 ± 224 45.34 < 0.001
Thalamus volume§ 7333 ± 778 7525 ± 793 7157 ± 639 3.65 0.028
Caudate volume§ 4084 ± 484 4031 ± 518 4197 ± 420 2.62 0.08
Putamen volume§ 6363 ± 808 5958 ± 727 6885 ± 687 20.28 < 0.001
OFC
Volume 13272 ± 1518 14282 ± 1558 13511 ± 1361 3.29 0.039
Cortical thickness¶ 2.57 ± 0.21 2.61 ± 0.23 2.54 ± 0.16 2.07 0.13
Surface area¶ 4671 ± 524 4980 ± 692 4789 ± 570 6.52 0.002
ACC
Volume¶ 4746 ± 718 4796 ± 703 4908 ± 880 1.73 0.018
Cortical thickness¶ 2.76 ± 0.25 2.81 ± 0.22 2.66 ± 0.23 5.58 0.004
Surface area¶ 1525 ± 213 1525 ±242 1656 ± 279 3.59 0.029
Insula
Volume¶ 7090 ± 720 7507 ± 765 7551 ± 879 7.84 0.001
Cortical thickness¶ 3.02 ± 0.20 3.01 ± 0.20 3.19 ± 0.18 38.54 < 0.001
Surface area¶ 2302 ± 280 2469 ± 277 2305 ± 320 8.24 < 0.001
Parahippocampal gyrus
Volume¶ 2325 ± 316 2186 ± 277 2566 ± 321 24.53 < 0.001
Cortical thickness¶ 2.78 ± 0.28 2.64 ± 0.25 3.01 ± 0.33 22.82 < 0.001
Surface area¶** 727 ± 94 727 ± 98 736 ± 101 0.86 0.42
Fusiform gyrus
Volume¶ 10359 ± 1454 10385 ± 1171 11415 ± 1191 18.27 < 0.001
Cortical thickness¶ 2.65 ± 0.20 2.64 ± 0.18 2.84 ± 0.19 39.40 < 0.001
Surface area¶ 3434 ± 451 3480 ± 429 3510 ± 407 1.64 0.20
ACC = anterior cingulate cortex; CUD = cannabis use disorder; NCUD = no cannabis use disorder; OFC = orbitofrontal cortex; SD = standard deviation.  
*Measures are adjusted for respectively intracranial volume, mean cortical thickness weighted by surface area and total surface area. In addition, all results are adjusted for age and slice 
thickness. 
†Volumes are measured in cubic millimetres, surface area is measured in square millimetres, and cortical thickness is measured in millimetres. 
‡Volumes significant from p < 0.01, cortical thickness significant from p < 0.02 and surface area significant from p < 0.03.  
§Based on the FreeSurfer segmentation output.  
¶Based on the FreeSurfer Desikan-Killiany Atlas. 
**Significant interaction between group status (i.e., CUD, NCUD or HC) and age.
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 frequency of cannabis use in any of the assessed regions 
 (Appendix, Tables S1 and S2).
When assessing the contribution of cortical thickness and cor­
tical surface area to the volume differences between patients and 
healthy controls, we found an effect of group in the anterior cin­
gulate gyrus, insula, parahippocampus and fusiform gyrus 
 (Table 3). Pairwise comparisons showed significantly thinner 
cortices in most ROIs (insula, parahippocampus and fusiform 
gyrus) for both patient groups compared with controls and in 
the anterior cingulate gyrus for the CUD group compared with 
controls (Appendix,  Table S5). With respect to the cortical sur­
face areas, we found an effect of group for the OFC and the in­
sula (Table 3). Pairwise comparisons of the OFC showed smaller 
cortical surface areas for the NCUD compared with the control 
Fig. 1: Mean volumes of the regions of interest per group, shown as percentage deviation of the healthy control (HC) group. ACC = anterior 
cingulate cortex; CUD = cannabis use disorder; GM = grey matter; NCUD = no cannabis use disorder; OFC = orbitofrontal cortex.
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Table 4: Pairwise comparisons of the regions with a significant effect of group on volume*
CUD v. control NCUD v. control CUD v. NCUD
Brain region β† SEb p value d‡ β† SEb p value d‡ β† SEb p value d‡
Amygdala§ –276.00 34.50 < 0.001 1.24 –355.55 45.50 < 0.001 1.73 –79.60 45.46 0.08
Putamen§ –505.79 117.45 < 0.001 0.70 –926.14 154.97 < 0.001 1.33 –420.36 154.83 0.007 0.52
Insula¶ –427.10 107.9 < 0.001 0.57 –197.00 142.40 0.17 230.13 142.27 0.11
Parahippocampal  
gyrus
–241.71 48.25 < 0.001 0.76 –409.40 63.66 < 0.001 1.23 –167.69 63.60 0.009
Fusiform gyrus¶ –1024.10 195.80 < 0.001 0.80 –1238.32 258.38 < 0.001 0.87 –214.19 258.14 0.41
CUD = cannabis use disorder; NCUD = no cannabis use disorder; SEb = standard error of b.  
*All results are adjusted for age, slice thickness and intracranial volume. Significant from p < 0.01. 
†Adjusted mean difference between the 2 groups. 
‡Calculated only for significant regions of interest. 
§Based on the FreeSurfer segmentation output.  
¶Based on the FreeSurfer Desikan-Killiany Atlas.
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group (d = 0.31) and for the CUD compared with the NCUD 
group (d = 0.54). Significantly smaller cortical surface areas 
were found in the insula for both patient groups compared 
with controls (CUD v. control: d = 0.01; NCUD v. control: d = 
0.53; Appendix, Table S6).
We assessed cortical symmetry in all 3 groups separately 
(Appendix, Table S7), showing cortical asymmetry in 3 of 
5 regions in the CUD group (ACC: t79 = 2.58, p = 0.012; insula: 
t79 = –2.40, p = 0.019; parahippocampus: t79 = 5.11, p < 0.001) and 
in the control group (OFC: t83 = 7.26, p < 0.001; ACC: t83 = 2.02, 
p = 0.047; insula: t83 = –8.09, p < 0.001). In the NCUD group, all 
5 ROIs showed left/right symmetry, as none of the regions 
significantly differed between the left and right hemisphere.
Discussion
In the present study we evaluated differences in grey matter 
volume, cortical thickness and cortical surface area in a 
large sample of patients with recent onset schizophrenia 
with and without comorbid cannabis use disorders and 
healthy controls using an ROI approach. As expected, pa­
tients with schizophrenia had significantly smaller volumes 
of most a priori–defined brain regions than healthy controls. 
Contrary to our expectations, patients in the CUD group 
had a larger volume of the putamen than those in the 
NCUD group, while differences in the other regions did not 
reach significance. Inconsistent results have been reported 
in the literature regarding volume differences between pa­
tients with and without CUDs, with most studies showing 
no differences or smaller volumes in patients with 
CUDs.10,16,46 Similar to our results, however, 2 studies re­
ported larger volumes in the CUD group than in the NCUD 
group.21,47 A possible explanation is that patients with CUDs 
represent a subgroup of patients that is intrinsically less 
vulnerable for schizophrenia than patients who never used 
cannabis (i.e., NCUD patients are a group in whom schizo­
phrenia developed without the extra risk factor of cannabis 
use and therefore could be intrinsically more vulnerable). 
This idea is supported by our finding of reduced asym­
metry in the NCUD group compared with the CUD and the 
control groups. Decreased cerebral lateralization in patients 
with schizophrenia could be caused by a deviation of the 
genetic mechanism underlying cerebral dominance (the hy­
pothesized “right­shift factor”) which may cause a vulner­
ability to schizophrenia.9 In line with this explanation, it has 
consistently been reported that patients who use cannabis 
perform better in several cognitive domains than patients 
who do not use cannabis.21,48,49 Based on these results, a 
neuro protective role of cannabis has been suggested. How­
ever, in a longitudinal study by Rais and colleagues,50 vol­
ume decreases in patients who use cannabis appeared at 
5­year follow­up, whereas no volume differences were ap­
parent at baseline, suggesting that long­term cannabis use is 
more likely neurodegenerative. This adverse effect of can­
nabis use is supported by the findings of a longitudinal 
study by González­Pinto and colleagues.51 Although at 
baseline no differences in clinical characteristics were found 
between the CUD and NCUD groups, patients who stopped 
using cannabis had a significantly better functional outcome 
than patients who never used cannabis and those who con­
tinued to use cannabis.51 In summary, these studies show 
that patients with CUDs could represent a subgroup of pa­
tients with schizophrenia who have a lower intrinsic vul­
nerability, but that continued cannabis use in these patients 
may have neurotoxic effects and is associated with a worse 
functional outcome. However, for the present cohort no 
long­term  follow­up data are available, so this theory can­
not be corroborated by our findings.
Other possible explanations for our finding of enlarged pu­
tamen volumes in the CUD group cannot be ruled out; for 
example, cannabis may have a direct neuroprotective effect 
on brain volumes. This could especially be the case when 
 using cannabis with a high concentration of cannabidiol.52 In 
addition, Malchow and colleagues53 found an increased 
N­acetyl aspartate:choline ratio using magnetic resonance 
spectroscopy in the left putamen in patients with comorbid 
cannabis use, indicating a neuro­ and membrane­protective 
effect of tetrahydrocannabinol.
However, given our finding that polysubstance use may 
contribute to the difference in putamen volume between the 
CUD and NCUD groups, another possible explanation is the 
role of this structure in addiction. The putamen — as part of 
the dorsal striatum — is a crucial structure in habit formation 
in individuals with chronic addictive behaviours. According to 
Everitt and Robbins,54 early stages of addiction are character­
ized by voluntary drug use related to its rewarding and moti­
vational effects, represented by hyperactivity of the ventral 
striatum. Later stages of addiction are characterized by in­
voluntary habitual or compulsive drug use, represented by hy­
peractivation of the dorsal striatum.54 The dorsal striatum (pu­
tamen), therefore, plays an important role in the progression 
from the initial reinforcing effects of drug use to habitual, com­
pulsive substance use,54,55 which might explain the larger vol­
ume of this area in the cannabis­dependent patient group.
With regard to the age at onset of regular cannabis use, we 
found no association with cortical brain volume, which is in 
accordance with findings of most studies published so far.30 
In line with findings in nonschizophrenic patients with 
CUDs,29 we found a trend association in our sample between 
caudate volume and frequency of use, with smaller volumes 
associated with more frequenct use. Other studies, however, 
did not include the caudate as an ROI. The lack of associa­
tions in other brain regions may be explained by the low 
variance in frequency of use (71% of the cannabis users were 
daily cannabis users). Studies included in the review by 
 Lorenzetti and colleagues29 included more diverse samples 
with varying frequencies of cannabis use.
As hypothesized, cortical thinning mainly drove volumet­
ric differences between patients and controls. However, we 
found no differences between the CUD and NCUD groups in 
cortical thickness. For cortical surface area, differences be­
tween the CUD and NCUD groups were found only in the 
OFC. Volumetric differences between the CUD and NCUD 
groups were expected to depend on cortical thinning, be­
cause environmental factors may influence cortical thickness 
more heavily than cortical surface area. 31 In our sample, 
 volumetric differences might have been too subtle to distin­
guish effects of thickness and surface area.
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Limitations
Our findings should be viewed in light of several limitations. 
First, although patients were in the early phase of a psychotic 
disorder, most of them used antipsychotic medication, which 
may have confounded our results, especially with regard to 
subcortical volumes. However, because the CUD and NCUD 
groups did not differ with respect to their use of antipsychotic 
medication, it is not likely that medication effects would ex­
plain the volume differences between these groups. The same 
goes for other potential confounders, such as age, presence of 
comorbid disorders (including DSM­IV drug diagnoses), dura­
tion of schizophrenia and other clinical variables.
A second limitation is that it was difficult to correct for nic­
otine use, because data were missing for 39 of 197 partici­
pants. This may be problematic, because nicotine use has 
been shown to affect regional brain volumes in healthy con­
trols and patients with schizophrenia. In healthy individuals, 
smoking seems mainly related to grey matter volume loss in 
the prefrontal regions and possibly in the insula and the ol­
factory gyrus.56­58 However, findings in patients with schizo­
phrenia are inconsistent. One ROI study reported smaller 
grey matter volumes in the hippocampus and the dorsolat­
eral prefrontal cortex,58 whereas another study reported 
larger grey matter volumes in the lateral prefrontal cortex 
and the superior temporal gyri,57 and a recent study found no 
grey matter volume differences between smoking and non­
smoking patients with schizophrenia.59 To control for the 
possible confounding effect of nicotine use, we decided to 
add nicotine use to the model as a covariate. The effect sizes 
remained very similar, but the difference in putamen volume 
between the CUD and NCUD groups was no longer signifi­
cant. A possible explanation is that polysubstance and nico­
tine use contribute to the difference in putamen volume be­
tween patients with and without CUDs. However, a more 
likely explanation for this combination of findings (similar ef­
fect sizes and loss of significance) is the reduced statistical 
power due to missing entries. In summary, the presence of a 
CUD seems independently associated with putamen volume, 
but we cannot completely rule out that the group differences 
in putamen volume were caused by nicotine rather than can­
nabis use; therefore, future studies should include healthy, 
nicotine­dependent controls.
A third limitation is the use of different scan protocols. Al­
though all participants were scanned on the same MRI scan­
ner, there were slight differences in scanning protocols. How­
ever, surface­based models like FreeSurfer have a strong 
robustness for differences in field strength, scanner upgrades 
and scanner manufacturer.60 In addition we included slice 
thickness in our statistical model to reduce this confounding 
effect. However, it was not possible to create a subset of 
 better­matched participants. Future studies should include 
participants undergoing exactly the same scanning protocol.
The strengths of our study include the large sample of pa­
tients with recent onset schizophrenia with and without 
CUDs. The few studies published so far on the influence of 
cannabis use on brain volumes in recent onset schizophrenia 
all have small sample sizes of fewer than 30 patients. In addi­
tion, our sample had a relatively short history of anti­
psychotic medication intake, minimizing the influence of 
anti psychotic medication on brain volumes, especially com­
pared with studies examining chronic patient cohorts.
Conclusion
Patients with schizophrenia (with and without a CUD) had 
smaller volumes of most brain regions than healthy controls. 
However the CUD and NCUD groups were mostly indistin­
guishable in the early phase of the disease, except for the 
larger putamen volumes in the CUD group. A possible expla­
nation for these results is that cannabis use promotes the on­
set of schizophrenia in less vulnerable individuals and that 
patients with schizophrenia and a comorbid CUD represent a 
subgroup of patients who could have a relatively favourable 
outcome if they stopped using cannabis.49 This explanation is 
supported by our finding of reduced asymmetry in the 
NCUD group compared with the CUD and control groups, 
which could be caused by a genetic vulnerability to schizo­
phrenia.9 Another possible explanation is the role of the puta­
men in habitual, compulsive substance use,54,55 which is sup­
ported by our finding that polysubstance use may drive the 
difference in putamen volume between groups. Therefore, 
future studies should elaborate on whether this finding rep­
resents differences in brain development between groups or 
whether addiction affects putamen volume.
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